We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

121 hedge funds and large institutions have $316M invested in Rigel Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more call options, than puts

Call options by funds: $3.05M | Put options by funds: $1.07M

69% more capital invested

Capital invested by funds: $187M → $316M (+$129M)

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

2% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 42

1% more funds holding

Funds holding: 120 → 121 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
121
Holders Change
+1
Holders Change %
+0.83%
% of All Funds
3.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
43
Reduced
42
Closed
18
Calls
$3.05M
Puts
$1.07M
Net Calls
+$1.99M
Net Calls Change
+$1.7M

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$6.86M
2
Goldman Sachs
Goldman Sachs
New York
+$4.75M
3
CAM
Cormorant Asset Management
Massachusetts
+$3.31M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.19M
5
CS
Candriam SCA
Luxembourg
+$2.08M

Top Sellers

1
DM
Deerfield Management
New York
-$5.2M
2
DCM
DAFNA Capital Management
California
-$4.32M
3
ACP
Acuta Capital Partners
California
-$2.14M
4
NI
Numeric Investors
Massachusetts
-$1.89M
5
SAM
Senzar Asset Management
New York
-$1.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
101
Legal & General Group
United Kingdom
$54K -$5.76K -201 -12%
Jane Street
102
Jane Street
New York
$40K +$31K +1,082 New
Creative Planning
103
Creative Planning
Kansas
$37K – – –
HighTower Advisors
104
HighTower Advisors
Illinois
$37K – – –
PHK
105
Point72 Hong Kong
Hong Kong
$26K +$20.6K +720 New
Victory Capital Management
106
Victory Capital Management
Texas
$24K +$18.9K +660 New
BNP Paribas Financial Markets
107
BNP Paribas Financial Markets
France
$23.9K +$8.29K +289 +80%
UBS Group
108
UBS Group
Switzerland
$22K +$16.3K +570 +1,900%
Simplex Trading
109
Simplex Trading
Illinois
$18K -$155K -5,413 -92%
PCM
110
Prelude Capital Management
New York
$17K -$70.2K -2,450 -84%
BJ
111
BlackRock Japan
Japan
$17K -$2.61K -91 -16%
CG
112
Cutler Group
California
$13K +$10.6K +370 +3,700%
AIM
113
Acrospire Investment Management
Illinois
$9K -$287 -10 -4%
Bank of Montreal
114
Bank of Montreal
Ontario, Canada
$6K +$4.3K +150 New
MA
115
MUFG Americas
New York
$5K -$1.92K -67 -34%
TCIM
116
TIAA CREF Investment Management
New York
$2.77K +$77.1K +2,689 +4%
Royal Bank of Canada
117
Royal Bank of Canada
Ontario, Canada
$2K -$631 -22 -31%
VOYA Investment Management
118
VOYA Investment Management
Georgia
$151 – – –
DM
119
Deerfield Management
New York
– -$5.2M -233,137 Closed
NI
120
Numeric Investors
Massachusetts
– -$1.89M -84,658 Closed
ACP
121
Acuta Capital Partners
California
– -$2.14M -74,775 Closed
GC
122
Globeflex Capital
California
– -$757K -33,953 Closed
PI
123
Putnam Investments
Massachusetts
– -$649K -29,102 Closed
TC
124
TFS Capital
Pennsylvania
– -$517K -23,176 Closed
IHM
125
Iguana Healthcare Management
New York
– -$335K -15,000 Closed
2 3 4
5
6

RIGL Hedge Fund Activity: Q3 2016 in Review

121 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2016, worth a combined $316M — up 69% from $187M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RIGL positions and 18 closed out — a net gain of 1 holder — while 43 added to existing stakes and 42 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $6.86M. The largest seller was Deerfield Management, exiting entirely with an estimated $5.2M sold.

  • 121 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2016, up from 120 in Q2 2016.
  • Funds reported $316M of Rigel Pharmaceuticals stock for Q3 2016, up 69% quarter-over-quarter.
  • 19 funds opened new Rigel Pharmaceuticals positions in Q3 2016 and 18 closed out, a net change of +1 holder.
  • The largest Rigel Pharmaceuticals buyer in Q3 2016 was Citadel Advisors, an estimated $6.86M added.
  • The largest Rigel Pharmaceuticals seller in Q3 2016 was Deerfield Management, an estimated $5.2M sold.

Based on aggregated 13F filings for Q3 2016.